BioXcell特色推荐——InVivoMAb anti-mouse CD40

一产品背景

CD40是一种48 kDa的I型跨膜糖蛋白，属于肿瘤坏死因子受体(TNFR)超家族。CD40广泛表达于抗原呈递细胞(APCs)，如树突状细胞、B细胞、巨噬细胞和单核细胞，以及非免疫内皮细胞、基底上皮细胞和一系列肿瘤。CD40与其配体CD154结合后，作为共刺激分子激活B细胞、树突状细胞、单核细胞和其他APCs。CD40在B细胞活化、分化、增殖和免疫球蛋白同种型转换以及树突状细胞成熟中起作用。激动性CD40单克隆抗体已被证明能激活APCs并促进抗肿瘤T细胞反应。克隆号FGK4.5抗体是一种激动性抗体，已被证明能激活表达CD40的APC。克隆号FGK4.5也可用于体外和体内抑制CD40/CD154相互作用。

二抗体的应用 Application& 产品信息

产品货号	BE0016-2
产品规格	1/5/25/50/100mg
抗体亚型	Rat IgG2a
推荐同型对照	InVivoMAb rat IgG2a isotype control, anti-trinitrophenol（货号：BE0089）
推荐抗体稀释液	InVivoPure™ pH 7.0 Dilution Buffer（货号：IP0070）
免疫原	Recombinant mouse CD40 fusion protein
应用	in vivo CD40 activation in vitro B cell stimulation/activation
产品形式	PBS, pH 7.0 Contains no stabilizers or preservatives
内毒素水平	<2EU/mg (<0.002EU/μg)
纯度	>95% Determined by SDS-PAGE
无菌处理	0.2 μM filtered
生产形式	从组织培养上清液中纯化得到。
纯化形式	Protein G
RRID	AB_1107647
分子量大小	150 kDa
保存条件	抗体原溶液应保存在4°C条件下，不要冷冻保存。

三产品已发表文献

用途	已发表文献文章
in vivo CD40 activation	Bauche, D., et al. (2018). “LAG3(+) Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1(+) Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis.” Immunity 49(2): 342-352 e345.
in vivo CD40 activation	Bartkowiak, T., et al. (2015). “Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.” Proc Natl Acad Sci U S A 112(38): E5290-5299
in vivo CD40 activation	Carmi, Y., et al. (2015). “Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity.” Nature 521(7550): 99-104.
in vivo CD40 activation	Conde, P., et al. (2015). “DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance.” Immunity 42(6): 1143-1158
in vitro B cell stimulation/activation	Xu, H., et al. (2015). “Regulation of bifurcating B cell trajectories by mutual antagonism between transcription factors IRF4 and IRF8.” Nat Immunol
in vivo CD40 activation	Erickson, J. J., et al. (2014). “Programmed death-1 impairs secondary effector lung CD8(+) T cells during respiratory virus reinfection.” J Immunol 193(10): 5108-5117
in vitro B cell stimulation/activation	Muppidi, J. R., et al. (2014). “Loss of signalling via Galpha13 in germinal centre B-cell-derived lymphoma.” Nature 516(7530): 254-258
n vivo CD40 activation	Rabenstein, H., et al. (2014). “Differential kinetics of antigen dependency of CD4+ and CD8+ T cells.” J Immunol 192(8): 3507-3517

详情请咨询 BioXcell 中国授权代理-优宁维生物